Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Caitlin E. Cox

September 01, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Conference News ISET 2024

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

Caitlin E. Cox

January 30, 2024

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

L.A. McKeown

November 15, 2021

News Daily News

Long-term Anticoagulation After Unprovoked VTE: New Insights

Shelley Wood

September 13, 2021

News Daily News

VTE Risk Higher After Oxford/AstraZeneca COVID-19 Vaccine, Study Affirms

Todd Neale

May 06, 2021

News Daily News

Lasers Can Aid Retrieval of Stubborn IVC Filters

Caitlin E. Cox

December 02, 2020

News Daily News

COVID-19 Clots Spur Both Arterial, Venous Events in Hospitalized Patients

Caitlin E. Cox

July 24, 2020

News Daily News

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Michael O'Riordan

July 13, 2020

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Caitlin E. Cox

June 25, 2020

News Daily News

German COVID-19 Autopsy Data Show Thromboembolism, ‘Heavy’ Lungs

L.A. McKeown

May 11, 2020

News Daily News

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus

Michael O'Riordan

April 29, 2020

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Daily News

Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk

Caitlin E. Cox

January 14, 2020

News Daily News

Testosterone Therapy Raises Risk of VTE Early but Not Beyond 6 Months

Michael O'Riordan

December 01, 2016

News Daily News

Ultrasound-Assisted Thrombolysis Fails to Boost Thrombus Resolution in Acute Iliofemoral DVT

Todd Neale

January 29, 2015

Advertisement

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

Long-term Anticoagulation After Unprovoked VTE: New Insights

VTE Risk Higher After Oxford/AstraZeneca COVID-19 Vaccine, Study Affirms

Lasers Can Aid Retrieval of Stubborn IVC Filters

COVID-19 Clots Spur Both Arterial, Venous Events in Hospitalized Patients

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

German COVID-19 Autopsy Data Show Thromboembolism, ‘Heavy’ Lungs

Pulmonary Embolism in COVID-19 Patients: New Numbers, Little Consensus

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk

Testosterone Therapy Raises Risk of VTE Early but Not Beyond 6 Months

Ultrasound-Assisted Thrombolysis Fails to Boost Thrombus Resolution in Acute Iliofemoral DVT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content